• Jupiter Neurosciences signed a definitive license with PharmAla for perpetual exclusive U.S. rights to ALA-002, valued up to USD 100 million.
• USD 3.3 million upfront payment includes USD 1.5 million cash, USD 1.8 million in common stock subject to a 120-day lock-up.
• Milestones include USD 3.3 million at Phase 3 first patient in, USD 20 million on U.S. NDA approval, sales-based payments up to USD 73.3 million.
• Royalty set at 3% of net sales, starting after the third commercial milestone.
• ALA-002 is an FDA NCE-designated, patented non-racemic MDMA candidate; PharmAla will supply GMP drug product under terms to be negotiated.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jupiter Neurosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607210713PRIMZONEFULLFEED9765373) on July 21, 2026, and is solely responsible for the information contained therein.